Achieve Life Sciences, Inc.: 5%+ holders

Achieve Life Sciences, Inc. has 17 Schedule 13D or 13G filings on record since 2025-07-16. 11 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

Holders

Purpose of Transaction (Item 4)

Tpg Gp A, LLC

The information set forth in or incorporated by reference in Items 2, 3, 5 and 6 of this Schedule 13D is incorporated by reference in its entirety into this Item 4. Securities Purchase Agreement TPG Auriga entered into a Securities Purchase Agreement (the "Securities Purchase Agreement") with the Issuer, dated as of April 15, 2026, pursuant to which it agreed to purchase, and the Issuer agreed to sell and issue, 6,877,580 shares of Common Stock and 6,877,580 accompanying Warrants at a collective price of $3.635 per combination of share of Common Stock and accompany Warrant (the "Private Placement"). On April 17, 2026, the Private Placement closed (the "Closing"). The aggregate purchase price of $25,000,003.30 paid by TPG Auriga for the shares of Common Stock and accompanying Warrants was funded by equity contributions of the limited partners of TPG Auriga. Pursuant to the Securities Purchase Agreement, on April 15, 2026, the Board of Directors of the Issuer appointed Lucian Iancovici, as designated by TPG Auriga, to serve as a director of the Issuer, effective April 17, 2026. The Issuer has agreed to nominate Dr. Iancovici for re-election to the Board of Directors at the Issuer's 2026 annual meeting of stockholders and the 2027 annual meeting of stockholders, until such time as TPG Auriga beneficially owns less than 5% of the Issuer's outstanding Common Stock. Registration Rights Agreement In connection with the Private Placement, TPG Auriga entered into a …The first part of Item 4 of the SCHEDULE 13D filed 2026-04-24; the filing has the rest

venBio Global Strategic Fund V, L.P.

The response to Item 3 of this Schedule 13D is incorporated herein by reference. The Reporting Persons acquired the securities reported herein for investment purposes. Subject to a number of factors, including market conditions and their general investment and trading policies, the Reporting Persons may, in the ordinary course of their business, dispose of the shares of Common Stock that they beneficially own. These dispositions may occur in open market transactions, privately negotiated transactions, or through other methods. Additionally, Fund V may distribute the shares of Common Stock that it directly holds to its limited partners. Dr. Royston, who is a member of General Partner V, is a director of the Issuer. The Reporting Persons, either directly or indirectly through Dr. Royston, may engage in discussions from time to time with the Board, the Issuer's management, or the Issuer's other stockholders. These discussions may be with respect to (i) acquiring or disposing shares of Common Stock or other securities of the Issuer (collectively, the "Securities"); (ii) maintaining or changing the Issuer's business, operations, governance, management, strategy, or capitalization; or (iii) implementing transactions that may relate to or may result in any matter set forth in paragraphs (a) through (j) of the instructions to Item 4 of Schedule 13D. Additionally, the Reporting Persons may acquire additional Securities through open market transactions, privately negotiated …The first part of Item 4 of the SCHEDULE 13D filed 2026-04-27; the filing has the rest

Timeline

Where this comes from

Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.

Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.

All recent stakesThat week's stakes